These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 36894639)

  • 21. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy.
    Qian J; Wang C; Wang B; Yang J; Wang Y; Luo F; Xu J; Zhao C; Liu R; Chu Y
    J Neuroinflammation; 2018 Oct; 15(1):290. PubMed ID: 30333036
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma.
    Gupta S; McCann L; Chan YGY; Lai EW; Wei W; Wong PF; Smithy JW; Weidler J; Rhees B; Bates M; Kluger HM; Rimm DL
    J Immunother Cancer; 2019 Sep; 7(1):254. PubMed ID: 31533832
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SOX10 Regulates Melanoma Immunogenicity through an IRF4-IRF1 Axis.
    Yokoyama S; Takahashi A; Kikuchi R; Nishibu S; Lo JA; Hejna M; Moon WM; Kato S; Zhou Y; Hodi FS; Song JS; Sakurai H; Fisher DE; Hayakawa Y
    Cancer Res; 2021 Dec; 81(24):6131-6141. PubMed ID: 34728538
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CRISPR screening identifies the deubiquitylase ATXN3 as a PD-L1-positive regulator for tumor immune evasion.
    Wang S; Iyer R; Han X; Wei J; Li N; Cheng Y; Zhou Y; Gao Q; Zhang L; Yan M; Sun Z; Fang D
    J Clin Invest; 2023 Dec; 133(23):. PubMed ID: 38038129
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy.
    Gao Y; Nihira NT; Bu X; Chu C; Zhang J; Kolodziejczyk A; Fan Y; Chan NT; Ma L; Liu J; Wang D; Dai X; Liu H; Ono M; Nakanishi A; Inuzuka H; North BJ; Huang YH; Sharma S; Geng Y; Xu W; Liu XS; Li L; Miki Y; Sicinski P; Freeman GJ; Wei W
    Nat Cell Biol; 2020 Sep; 22(9):1064-1075. PubMed ID: 32839551
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma.
    Cerezo M; Guemiri R; Druillennec S; Girault I; Malka-Mahieu H; Shen S; Allard D; Martineau S; Welsch C; Agoussi S; Estrada C; Adam J; Libenciuc C; Routier E; Roy S; Désaubry L; Eggermont AM; Sonenberg N; Scoazec JY; Eychène A; Vagner S; Robert C
    Nat Med; 2018 Dec; 24(12):1877-1886. PubMed ID: 30374200
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IFNγ induces PD-L1 overexpression by JAK2/STAT1/IRF-1 signaling in EBV-positive gastric carcinoma.
    Moon JW; Kong SK; Kim BS; Kim HJ; Lim H; Noh K; Kim Y; Choi JW; Lee JH; Kim YS
    Sci Rep; 2017 Dec; 7(1):17810. PubMed ID: 29259270
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MYC activation impairs cell-intrinsic IFNγ signaling and confers resistance to anti-PD1/PD-L1 therapy in lung cancer.
    Alburquerque-Bejar JJ; Navajas-Chocarro P; Saigi M; Ferrero-Andres A; Morillas JM; Vilarrubi A; Gomez A; Mate JL; Munoz-Marmol AM; Romero OA; Blecua P; Davalos V; Esteller M; Pros E; Llabata P; Torres-Diz M; Esteve-Codina A; Sanchez-Cespedes M
    Cell Rep Med; 2023 Apr; 4(4):101006. PubMed ID: 37044092
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of Small-Molecule Inhibitors of the PD-1/PD-L1 Axis That Promote PD-L1 Internalization and Degradation.
    Wang T; Cai S; Cheng Y; Zhang W; Wang M; Sun H; Guo B; Li Z; Xiao Y; Jiang S
    J Med Chem; 2022 Mar; 65(5):3879-3893. PubMed ID: 35188766
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion.
    Lu C; Paschall AV; Shi H; Savage N; Waller JL; Sabbatini ME; Oberlies NH; Pearce C; Liu K
    J Natl Cancer Inst; 2017 Jan; 109(6):. PubMed ID: 28131992
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Flow Cytometry Analysis of Surface PD-L1 Expression Induced by IFNγ and Romidepsin in Ovarian Cancer Cells.
    Padmanabhan S; Zou Y; Vancurova I
    Methods Mol Biol; 2020; 2108():221-228. PubMed ID: 31939184
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
    Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
    Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells.
    Wang H; Fu C; Du J; Wang H; He R; Yin X; Li H; Li X; Wang H; Li K; Zheng L; Liu Z; Qiu Y
    J Exp Clin Cancer Res; 2020 Feb; 39(1):29. PubMed ID: 32024543
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oxymatrine reduces expression of programmed death-ligand 1 by promoting DNA demethylation in colorectal cancer cells.
    Hua S; Gu M; Wang Y; Ban D; Ji H
    Clin Transl Oncol; 2021 Apr; 23(4):750-756. PubMed ID: 32737836
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of the PD-1/PD-L1 axis in human autoimmune thyroid disease: Insights into pathogenesis and clues to immunotherapy associated thyroid autoimmunity.
    Álvarez-Sierra D; Marín-Sánchez A; Ruiz-Blázquez P; de Jesús Gil C; Iglesias-Felip C; González Ó; Casteras A; Costa RF; Nuciforo P; Colobran R; Pujol-Borrell R
    J Autoimmun; 2019 Sep; 103():102285. PubMed ID: 31182340
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interferon-γ induces tumor resistance to anti-PD-1 immunotherapy by promoting YAP phase separation.
    Yu M; Peng Z; Qin M; Liu Y; Wang J; Zhang C; Lin J; Dong T; Wang L; Li S; Yang Y; Xu S; Guo W; Zhang X; Shi M; Peng H; Luo X; Zhang H; Zhang L; Li Y; Yang XP; Sun S
    Mol Cell; 2021 Mar; 81(6):1216-1230.e9. PubMed ID: 33606996
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Regulation of PD-L1 posttranslational modification and its application progress in tumor immunotherapy].
    Su Y; Wang Q; Ru Y; Dong J; Li X; Zhang Z
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 Nov; 38(11):1036-1043. PubMed ID: 36328434
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Control of pathogenic effector T-cell activities in situ by PD-L1 expression on respiratory inflammatory dendritic cells during respiratory syncytial virus infection.
    Yao S; Jiang L; Moser EK; Jewett LB; Wright J; Du J; Zhou B; Davis SD; Krupp NL; Braciale TJ; Sun J
    Mucosal Immunol; 2015 Jul; 8(4):746-59. PubMed ID: 25465101
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells.
    Homma S; Hayashi K; Yoshida K; Sagawa Y; Kamata Y; Ito M
    Int Immunopharmacol; 2018 Jan; 54():39-45. PubMed ID: 29100036
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PDL1 is expressed in the islets of people with type 1 diabetes and is up-regulated by interferons-α and-γ via IRF1 induction.
    Colli ML; Hill JLE; Marroquí L; Chaffey J; Dos Santos RS; Leete P; Coomans de Brachène A; Paula FMM; Op de Beeck A; Castela A; Marselli L; Krogvold L; Dahl-Jorgensen K; Marchetti P; Morgan NG; Richardson SJ; Eizirik DL
    EBioMedicine; 2018 Oct; 36():367-375. PubMed ID: 30269996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.